Multipl Miyelomda D Vitamini Düzeyinin Kemik Lezyonları ve Prognostik Faktörler Üzerine Etkileri

Amaç: Birkaç çalışma, düşük D vitamini düzeyinin, hematolojik malignitelerin artmış insidansı ve kötü prognozu ile ilişkili olduğunu bildirmiştir. Biz bu çalışmada multipl miyelomlu hastalarda, 25-hidroksivitamin D [25(OH)D] düzeyi ile kemik lezyonları ve prognostik faktörler arasındaki ilişkiyi araştırdık. Gereç ve Yöntemler: Yeni tanı almış 184 multipl miyelom hastası değerlendirildi. Tam kan sayımı, biyokimyasal parametreler, serum 25(OH)D düzeyi, litik kemik lezyonu ve kırık varlığı, hastalık evresi kaydedildi. Hastalar 25(OH)D düzeyine göre 3 gruba ayrıldı; eksik (

The Effects of Vitamin D Level on Bone Lesions and Prognostic Factors in Multiple Myeloma

Objective: Several studies have found that low vitamin D levels are associatedwith an increased risk of hematologic malignancies and a poor prognosis. In thisstudy, we investigated the relationship between 25-hydroxyvitamin D levels andbone lesions as well as prognostic factors in patients with multiple myeloma.Materials and Methods: We evaluated 184 people who had just been diagnosedwith multiple myeloma. Complete blood count, biochemical parameters, serum25-hydroxyvitamin D [25(OH)D] level, presence of lytic bone lesion and fracture,and disease stage were all recorded. The patients were divided into three groupsbased on their 25(OH)D levels: deficient (

PDF

___

1. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 2013; 12: 976-89.
2. Gorle RM , Kumar MA, Ayyagari S. Effect of serum vitamin D deficiency in the prevalence of haematological malignancies. Int J Clin Biochem Res 2018; 5: 185-90.
3. Medrano M, Carrillo-Cruz E, Montero I, Perez-Simon JA. Vitamin D: Effect on Haematopoiesis and Immune System and Clinical Applications. Int J Mol Sci 2018; 19: 2663.
4. Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer--ready for prime time? N Engl J Med 2011; 364: 1385-7.
5. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51: 311-36.
6. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700.
7. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, et al. Vitamin D insufficiency and prognosis in nonHodgkin’s lymphoma. J Clin Oncol 2010; 28: 4191-8.
8. Lee HJ, Muindi JR, Tan W, Hu Q, Wang D, Liu S, et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer 2014; 120: 521-9.
9. Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol 2017; 2017: 4812637.
10. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005; 16: 1223- 31.
11. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol 1998; 103: 902-10.
12. Ong MW, Salota R, Reeman T, Lapsley M, Jones L. Artefactual 25-OH vitamin D concentration in multiple myeloma. Ann Clin Biochem 2017; 54: 716-20.
13. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30.
14. Bringhurst FR, Demay MB, Kronenberg HM. Chapter 402: Bone and Mineral Metabolism in Health and Disease. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine, 16th ed. New York: MCGraw-Hill; 2005: 2238-86.
15. Holick MF. Vitamin D: a D-Lightful health perspective. Nutr Rev 2008 ;66(10 Suppl 2): 182-94.
16. Hyppönen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a crosssectional study in the 1958 British Birth Cohort. Diabetes 2008; 57: 298-305.
17. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007; 103: 708-11.
18. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005; 16: 83-95.
19. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128: 1414-24.
20. Chandler PD, Buring JE, Manson JE, Giovannucci EL, Moorthy MV, Zhang S, et al. Circulating Vitamin D Levels and Risk of Colorectal Cancer in Women. Cancer Prev Res (Phila) 2015; 8: 675-82.
21. Zhang H, Zhang H, Wen X, Zhang Y, Wei X, Liu T. Vitamin D Deficiency and Increased Risk of Bladder Carcinoma: A MetaAnalysis. Cell Physiol Biochem 2015; 37: 1686-92.
22. Burwick N. Vitamin D and plasma cell dyscrasias: reviewing the significance. Ann Hematol 2017; 96: 1271-7.
23. Maier GS, Horas K, Kurth AA, Lazovic D, Seeger JB, Maus U. Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma. Anticancer Res 2015; 35: 6281-5.
24. Hudzik S, Snoad B, Mousa L, Sborov DW, Williams N, Jones D, et al. The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics. Blood 2015; 126: 5336.
25. Alvin C Ng, Kumar SK, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 2009; 84: 397-400.
26. Graklanov V, Popov V, Raycheva R. Serum Levels of Vitamin D in Patients with Multiple Myeloma. Folia Med (Plovdiv) 2020; 62: 730-5.
27. Thomas X, Chelghoum Y, Fanari N, Cannas G. Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies. Hematology 2011; 16: 278-83.
28. Wang W, Li G, He X, Gao J, Wang R, Wang Y, et al. Serum 25-hydroxyvitamin D levels and prognosis in hematological malignancies: a systematic review and meta-analysis. Cell Physiol Biochem 2015; 35: 1999-2005.
29. Lauter B, Schmidt-Wolf IG. Prevalence, Supplementation, and Impact of Vitamin D Deficiency in Multiple Myeloma Patients. Cancer Invest 2015; 33: 505-9.
30. Gedik H, Yokus O, Hilmi Dogu M, Aydinli F, Eren R, Altindal S. Vitamin D deficiency and its effects on patients with multiple myeloma. Hematol Transfus Int J 2017; 5: 195-9.
31. Nath K, Ganeshalingam V, Ewart B, Heyer E, Watt K, Birchley A, et al. A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia. Support Care Cancer 2020; 28: 1249-54.
32. Diamond T, Golombick T, Manoharan A. Vitamin D status may effect the skeletal complications of multiple myeloma. Am J Hematol 2010; 85: 302-3.
33. Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 2008; 142: 492-4.